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Abstract 
 
Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived 
neurotrophic factor (MANF) form a novel neurotrophic factor family due to their unique 
structure and different mode of action when compared to classical neurotrophic factors. 
CDNF and MANF have shown to protect dopaminergic neurons in Parkinson’s disease 
animal models and therefore they are considered potential therapy agents. However, their 
target molecules, i.e., putative receptor(s) and signalling pathways are still unknown.  
78 kDa glucose-regulated protein (GRP78) member of the heat shock protein 
(HSP) family is a major chaperone that under Endoplasmic Reticulum (ER) stress 
conditions is up-regulated and prevents protein aggregation as well as facilitates 
degradation of misfolded proteins. It locates mainly in the ER but location can change in 
different conditions. In cancer research, GRP78 has been found highly expressed on the 
surface of cancer cells where it regulates critical oncogenic signalling pathways. For 
example, it was recently shown that Par-4 (Prostate apoptosis response-4) induces 
apoptosis via activation of caspase-3 by binding to GRP78, expressed at the surface of 
cancer cells.  
GRP78 has been shown capable of relocating extracellularly also in neurons. 
Especially, it was recently shown that accumulating extracellular α-synuclein induces an 
increase in surface-exposed GRP78 in cultured neurons. α-synuclein interacts with cell 
surface GRP78 and activates a signalling cascade affecting the morphology and dynamics 
of actin cytoskeleton. Our group has recent, yet unpublished data suggesting that CDNF 
and MANF interact with GRP78 protein. The emerging role for GRP78 also in the 
neurodegeneration requests further investigation on its possible interaction with CDNF 
and MANF and on the biological meaning of that interaction. 
In order to test whether CDNF and MANF would interact with cell surface GRP78 
and possibly compete with par-4 for the binding and in this way prevent apoptosis, we 
built a plasmid that would guide the expression and extracellular localization of GRP78 
in the transfected cells. We transfected HEK293 cells with this plasmid and incubated 
them for 24h with two concentrations of par-4. We could see a trend of increasing 
apoptosis in PAR-4 –treated cells, but this was not enhanced in the cells expressing 
GRP78 extracellularly, as we had hypothesised. Thus we did not continue further with 
testing CDNF and MANF on this setting. 
 
 
Transfected HEK293 cells were incubated with alkaline phosphatase tagged -
MANF or CDNF (AP-MANF or AP-CDNF) and using the alkaline phosphatase substrate 
pNitrophenylphosphate (pNPP), we were able to study the binding between GRP78 and 
CDNF and MANF. Even though we could not prove the cell surface GRP78 interaction 
with MANF with this method, we show a high affinity binding between cell surface 
GRP78 and CDNF when transfected cells are incubated with different concentrations of 
AP-CDNF. 
  
 
 
Keywords: Parkinson's disease, GRP78, CDNF, MANF, protein-protein interactions, 
neuroprotection, ER stress 
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1. Review of the literature  
1.1 Parkinson’s Disease  
 
Just after Alzheimer’s disease, Parkinson’s disease (PD) is the second most common 
neurodegenerative disease (Van Den Eeden et al., 2003) and the most common age-
related motor disorder (de Lau & Breteler, 2006) affecting about 1% of the elderly (de 
Rijk et al., 1995). As age is a significant risk factor and with the constant increase of the 
elderly population, the prevalence of PD is predicted to increase sharply, doubling its 
numbers in 25 years (Reeve, Simcox, & Turnbull, 2014). 
PD is characterized by two major aspects: the accumulation of intraneuronal 
Lewy-bodies/Lewy-neurites (LBs/LNs) containing misfolded fibrillar α-Synuclein and 
the selective degeneration of midbrain dopamine (DA) neurons in the substantia nigra 
pars compacta (SNpc) and their striatal projections (nigrostriatal pathway)(Fearnley & 
Lees, 1991). These two aspects disrupt the neural circuitry that controls movements and 
lead to PD’s major symptoms: bradykinesia, slowness of movement, resting tremor, 
rigidity, gait dysfunctions and postural instability. Motor symptoms appear when there is 
approximately 80% reduction in striatal DA (Lang & Lozano, 1998aa; 1998bb). Several 
non-motor symptoms such as impairment of smell, autonomic dysfunctions, depression, 
lack of motivation, sleep disorders and later on reduced cognitive abilities and dementia 
are also associated with the disease.  
Current therapeutic interventions fail to halt the progression of the disease, but 
substantially improve functional capacity and the quality of life. The initial treatment, and 
currently the most effective one, is Levodopa in combination with peripheral dopa 
decarboxylase inhibitor (benserazide or carbidopa). Even though L-dopa improves the 
motor symptoms by 20-70%, it is associated with significant complications such as the 
“wearing off” effect, rapid fluctuations of the motor state (“on-off”), levodopa-induced 
dyskinesias and other motor complications (Cotzias, Papavasiliou, & Gellene, 1969). 
Catechol-o-methyl-transferase inhibitors, DA agonists and nondopaminergic therapy are 
alternative modalities in the management of PD and may be used concomitantly with 
levodopa or one another. 
A way to overcome motor complications resulting from L-dopa therapy is the 
continuous administration of soluble L-dopa (duodopa) through a portable pump directly 
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into the duodenum or the upper jejunum by a permanent tube via gastro-jejunostomy 
enabling a constant L-dopa plasma concentration achieving a reduction of more than 50% 
of refractory “off” periods of immobility and dyskinesias. 
Neurosurgery is considered when optimal pharmacotherapy fails to control the 
motor symptoms. Bilateral deep brain stimulation of the subthalamic nucleus or the 
internal segment of the globus pallidus improves the motor symptoms with clear 
reduction in the drug-induced involuntary movements (Lees, Hardy, & Revesz, 2009). 
Despite the recent advances in PD therapy, it is far from optimal and the only 
goals achieved so far include alleviation of the symptoms and disability delayed by 
several years. Future therapies should focus on stopping and reversing the progression of 
the disease. 
 
1.2 Animal models of Parkinson’s Disease 
 
To gain insights into the pathophysiology of PD and on the other hand to develop new 
ways to treat it, PD experimental animal models, were developed and are divided into two 
main categories: toxic and genetic.  
Despite all the efforts, none of the currently available models can phenocopy PD 
due to lack of some specific neuropathological and/or behavioural features. Researchers 
should aim at electing the optimal model with appropriate strengths for investigating the 
issue and with weaknesses that will not invalidate the outcome of the experiment.  
Table 1 summarizes the general features of the main PD models. 
 
 
 
 
 
 
 
 
 
11 
 
 Animal model Motor 
behaviour 
SNC neuron 
loss 
Striatal 
DA loss 
Lewy 
body/Syn 
pathology 
 
Toxin 
based 
MPTP (1-methyl-
4phenyl-1,2,3,6-
tetrahydropyridine) 
Mice 
Reduced 
locomotion, 
bradykinesia 
*** *** NO 
 MPTP Monkeys Reduced 
locomotion, 
altered 
behaviour, 
tremor and 
rigidity 
*** *** Only MPTP-
injected 
monkeys show 
intraneuronal 
inclusions, 
LBs-like 
 6-OHDA (6-
hydroxydopamine) 
rat and mice 
Reduced 
locomotion, 
altered 
behaviour 
*** *** NO 
Genetic 
mutations 
  
α-synuclein Altered 
behaviour 
reduced or 
increased 
motor activity 
* Not 
consistent 
* * (in old 
animals) 
 LRKK2 (Leucine-
rich repeat kinase 
2)  
Mild 
behavioural 
alteration 
NO NO NO 
 PINK1 (PTEN-
induced putative 
kinase 1) 
No obvious 
alterations or 
reduced 
locomotion 
NO NO NO 
 Parkin No obvious 
alterations or 
reduced 
locomotion 
NO * NO 
 
*** - severe loss ; ** - moderate loss ; * - mild loss. Adapted from (Blesa & Przedborski, 2014) 
 
Table 1. Animal Models of Parkinson’s disease 
 
 
12 
 
1.3 Neurochemical and Neuropathological features of PD 
 
The cell bodies of nigrostriatal neurons are found in the SNpc and they project to two 
dorsal regions within the striatum: caudate and putamen. In PD, depletion of DA is most 
pronounced in the putamen (figure 1) (Price, Farley, & Hornykiewicz, 1978). 
The selective vulnerability of the SNpc neurons when compared to the VTA 
neurons can probably be explained by their unique physiological properties. For example, 
studies have shown that the specific pacemaking activity of the SNpc neurons using L-
type Ca2+ channels and ATPsensitive K+ channels is a likely cause of increased cellular 
stress (Guzman et al., 2010; Liss et al., 2005; Mosharov et al., 2009; Nedergaard, Flatman, 
& Engberg, 1993). 
SNpc DA neurons start degenerating at their terminals in striatum before also the 
somas in SNpc disappear in a process called “dying back”. The neurotoxin MPTP (1-
methyl-4phenyl-1,2,3,6-tetrahydropyridine) monkey and mouse models have shown that 
systemic injections produce relatively more robust deﬁcits in the striatum than in the 
midbrain (Herkenham et al., 1991; Wu et al., 2003). In addition, estimation studies 
showed that at the onset of PD symptoms, only approximately 30% of SNpc DA neurons 
were lost (Cheng, Ulane, & Burke, 2010), implying that the majority of the neurons are 
viable at this point, i.e. the dying neurons first lose their phenotypic markers, such as 
terminal functionality, but retain much of their cytoarchitectural structure.  
This phenotype loss provides the possibility of neuroregenerative therapy aiming 
at restoring the function of the still viable DA neurons (Domanskyi, Saarma, & Airavaara, 
2015). 
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Figure 1. Neuropathology of Parkinson’s disease. (A) Schematic representation of the normal 
nigrostriatal pathway (in red). DA neurons whose cell bodies are located in the substantia nigra pars 
compacta (SNpc; see arrows) project (thick solid red lines) to the basal ganglia and synapse in the striatum 
(i.e., putamen and caudate nucleus). The normal pigmentation of the SNpc is produced by neuromelanin 
within the DA neurons. (B) Schematic representation of the diseased nigrostriatal pathway (in red). There 
is a marked loss of DA neurons that project to the putamen (dashed line) and a much more modest loss of 
those that project to the caudate (thin red solid line). Depigmentation of the SNpc due to loss of DA neurons 
(i.e., loss of dark-brown pigment neuromelanin; arrows). Adapted from (Dauer & Przedborski, 2003). 
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1.4 Molecular and cellular pathogenesis of PD 
 
Having no specific known cause (idiopathic), PD has been considered a prototypical 
nongenetic disorder. However, the study of distinct genetic loci for rare Mendelian forms 
of PD, which account for 5-10% of total patient population (Lesage & Brice, 2009), has 
provided new important insights to the molecular and cellular pathogenesis.  
Genome Wide Association studies (GWASs) are used to examine many common 
genetic variants in different individuals by comparing the DNA sequence between 
individuals with varying phenotypes for a particular trait or disease. GWASs have 
highlighted several genes where a mutation triggers degeneration of SNpc DA neurons in 
familial forms of PD. Genetic animal models are based on these familial forms of PD, 
such as the α-synuclein, LRKK2, PINK1 and Parkin animal models (table 1). These 
mutations alter cellular and molecular mechanisms such as mitochondrial dysfunction, 
oxidative stress, endoplasmic reticulum (ER) stress and impairment of the ubiquitin-
proteasome system (UPS). Accumulating evidence suggests that these malfunctions may 
represent a common molecular pathogenesis pathway shared by both sporadic and 
familial forms of PD (Moore, West, Dawson, & Dawson, 2005). 
 
1.4.1 Mitochondrial dysfunction and oxidative stress 
 
One of the first, and most relevant hypotheses for PD pathogenesis relates to increased 
oxidative stress in mesencephalic DA neurons. In oxidative stress an imbalance between 
reactive oxygen species (ROS) production and the cell’s ability to clear the reactive 
intermediates happens leading to the production of peroxides and free radicals that cause 
damage to all components of the cell, including proteins and DNA. An increase in DA 
metabolism and reactive iron together with impaired antioxidant defence pathways, can 
cause mitochondrial dysfunction, excess hydrogen peroxide and other ROS (Jenner, 
2003) which will eventually lead to cell death. 
The discovery that MPTP blocks the mitochondrial electron transport chain by 
inhibiting complex I spotlighted oxidative phosphorylation defect as a possible 
pathogenesis mechanism of PD (Kindt, Heikkila, & Nicklas, 1987). Complex I defect 
decreases ATP synthesis and increases production of ROS which would certainly 
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contribute to neuronal degeneration in PD. Consistent ﬁndings of decrements in complex-
I activity in the SNpc of sporadic PD patients further support this hypothesis, even though 
their cause is unknown (Schapira et al., 1990). 
In vitro studies using cybrids (cells lines engineered to contain mitochondria 
derived from platelets of PD patients) have shown reduced complex I activity, caused by 
mutations in mtDNA. It remains unknown whether these mutations arise somatically or 
are inherited and such mutations have not been identified in sporadic PD patients 
(Swerdlow et al., 1996).  
PD animal models (such as nonhuman primate MPTP model) consistently show 
that complex I inhibition leads to the accumulation of LBs-like α-synuclein positive 
inclusions, suggesting α-synuclein aggregation as a downstream consequence of 
mitochondrial dysfunction (Forno, Langston, DeLanney, & Irwin, 1988; Manning-Bog et 
al., 2002; Sherer et al., 2002). Implications that α-synuclein is even required for mediating 
the downstream effects of complex-I inhibition were demonstrated by α-synuclein 
knockout mice which show resistance to the neurotoxic effects of MPTP and α-synuclein 
transgenic mice that show enhanced toxicity  (Dauer et al., 2002; Song, Shults, Sisk, 
Rockenstein, & Masliah, 2004).  
 
1.4.2 Misfolding and Aggregation of Proteins and Impairment of 
the Ubiquitin-Proteasome System 
 
 
The fact that the abnormal deposition of proteins within the brain is a common feature of 
age-related neurodegenerative disorders suggests that this event is toxic to the neurons 
(Dauer & Przedborski, 2003). When misfolded proteins accumulate, cells induce the 
production of chaperones which are proteins that assist the covalent folding or unfolding 
and the assembly or disassembly of other macromolecular structures. If not properly 
refolded, misfolded proteins are targeted for proteasomal degradation by binding of a 
polyubiquitin chain. As age progresses, chaperone expression is impaired as well as 
proteasome activity (Salganik et al., 2015).  
In PD, α-synuclein, a presynaptic terminal-enriched protein that is prone to 
misfolding and aggregation, is the major component of LBs (Spillantini et al., 1997). 
These intraneuronal inclusions are highly more common in diseased brain when 
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compared to normal brain (Braak et al., 2003) and can physically disrupt cellular 
topography, provoke ER stress (Smith et al., 2005), mitochondrial dysfunction (Hsu et 
al., 2000) and impairment in protein quality control systems (Cuervo, Stefanis, 
Fredenburg, Lansbury, & Sulzer, 2004; Tanaka et al., 2001). Cell death would follow 
after prolonged periods of these alterations. 
Using different experimental models, it has been shown that various exogenous 
toxins linked to PD (pesticides, herbicides and metal ions) accelerate the aggregation of 
α-synuclein (Manning-Bog et al., 2002; Sherer, Kim, Betarbet, & Greenamyre, 2003; 
Uversky, Li, Bower, & Fink, 2002) further supporting a gene-environment interaction in 
disease pathogenesis. 
A mutation or an over-expression of α-synuclein appears to affect a wide range of 
pathways and cellular functions including ER-to-Golgi transport, Golgi homeostasis, 
presynaptic trafficking, endocytosis, autophagy, the ubiquitin- proteasome system, ER 
and oxidative stress (Oaks, Marsh-Armstrong, Jones, Credle, & Sidhu, 2013; Snead & 
Eliezer, 2014; Thayanidhi et al., 2010; Winslow et al., 2010).  
Importantly, this accumulation of α-synuclein causes ER stress and activation of the 
unfolded protein response (UPR) causing apoptosis if unresolved (Smith et al., 2005). 
 
1.5 ER stress, UPR and GRP78 
 
The ER is an intracellular organelle that contributes to the proper folding and processing 
of nascent translated proteins destined for secretion. Under normal physiological 
conditions, unfolded, misfolded or aggregated proteins are degraded. Accumulating 
unfolded proteins in the ER lumen may trigger ER stress and activate UPR. This is a 
signal-transduction pathway that counteracts ER stress (Szegezdi, Logue, Gorman, & 
Samali, 2006) with three aims:  initially to restore normal function of the cell by halting 
protein translation, degrading misfolded proteins, and activating the signalling pathways 
that lead to increased production of molecular chaperones involved in protein folding. If 
these objectives are not achieved within a certain time span or the disruption is prolonged, 
the UPR leads to apoptosis. 
 One of the most important molecules mediating the ER stress and subsequent UPR 
is the chaperone 78-kDa glucose-regulated protein (GRP78). GRP78 (also referred to as 
BiP or HSPA5), is a member of the heat shock protein 70 (HSP70) superfamily and is 
17 
 
evolutionarily conserved from yeast to human (Ni & Lee, 2007). GRP78 contains a signal 
peptide that targets it to the ER: a carboxyl KDEL motif for retrieval from the Golgi 
apparatus leading to ER retention (Munro & Pelham, 1986). 
Having ATPase activity, GRP78 complexes with nascent polypeptides and is 
critical for their folding and maturation in the ER. During ER stress, GRP78 is up-
regulated and prevents protein aggregation as well as facilitates degradation of misfolded 
proteins. The UPR is mediated through three ER transmembrane receptors: inositol-
requiring enzyme 1 (IRE1), pancreatic ER kinase-like ER kinase (PERK), and activating 
transcription factor 6 (ATF6),  GRP78 binds to and maintains the transmembrane ER 
stress sensors (PERK, IRE1, and ATF6) in their inactive forms, and upon ER stress, 
GRP78 is released  resulting in the activation of  signalling pathways, impacting both cell 
survival and apoptosis (figure 2) (Bertolotti, Zhang, Hendershot, Harding, & Ron, 2000; 
Luo & Lee, 2013). Phosphorylated PERK blocks general mRNA translation by 
phosphorylating eukaryotic initiation factor 2 (eIF2) α subunit. However, transcription 
factor ATF4 is produced despite translational block to restore ER homeostasis, or later 
CHOP to trigger the apoptotic response. ATF6 and IRE1 pathways regulate the 
expression of ER chaperone genes and IRE1 degrades mRNA and, through spliced XBP1, 
induces the expression of genes for protein degradation (Voutilainen, Arumae, Airavaara, 
& Saarma, 2015) (Wang, Wey, Zhang, Ye, & Lee, 2009). 
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Figure 2. GRP78 regulates ER stress–signalling pathways leading to UPR survival and apoptosis 
responses. In non-stressed cells, the ER-transmembrane signalling molecules (ATF6, IRE1, and PERK) 
and ER-associated caspases (murine caspase-12/human caspase 4) are maintained in an inactive state 
through binding to GRP78. After ER stress, such as protein misfolding, GRP78 is titrated away, and the 
survival pathways are activated to block further damage. However, when the stress is too severe, apoptotic 
responses are triggered, which eventually lead to cell death. Reprinted from (Wang et al., 2009). 
 
 
 
GRP78 has been considered to be an ER lumenal protein, but recent studies 
indicate it can be detected in other cellular locations including the cell surface, cytosol, 
mitochondria and the nucleus assuming novel functions (Lee, 2014; Luo & Lee, 2013; 
Ni, Zhang, & Lee, 2011). In cancer cells, GRP78 is highly expressed at the cell surface, 
a process that is enhanced by elevated ER stress. On the cell surface GRP78 regulates 
critical oncogenic signalling pathways and it is emerging as a target for anti-cancer 
therapy (Arap et al., 2004; Lee, 2014). However, because GRP78 does not contain 
classical transmembrane domains, its mechanism of transport and its anchoring at the cell 
surface are poorly understood. In addition, the fact that different cell lines rely on different 
mechanisms for GRP78 cell surface translocation implies that the process depends on cell 
context (Tsai et al., 2015). 
GRP78 has the ability to form complexes with other proteins on the cell surface 
and play an important role in signalling transduction (Burikhanov et al., 2009). Prostate 
apoptosis response-4 (Par-4) is a proapoptotic protein with intracellular functions in the 
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cytoplasm and nucleus. Short exposure to ER stress inducing agents increases cellular 
secretion of Par-4. Through transfection of different cancer cell lines with a plasmid 
cloned with GRP78 with a transmembrane domain cDNA, it was shown that extracellular 
Par-4 induces apoptosis by binding to GRP78, expressed at the surface of cancer cells. 
The interaction of extracellular Par-4 and cell surface GRP78 led to apoptosis via ER 
stress and activation of the FADD/caspase-8/caspase-3 pathway (Burikhanov et al., 
2009). 
 
1.6 Neurotrophic factors and clinical trials 
 
Neurotrophic factors (NTFs) are an important group of secreted proteins regulating the 
life and death of neurons during and after development. Different NTFs affect specific 
sets of neuronal subpopulations. During developmental periods of programmed cell death 
in the Peripheral Nervous System (PNS), NTFs prevent apoptosis and regulate the 
number of neurons innervating the target tissue. According to the classical NTF theory, 
target tissues produce trophic molecules in limited amounts, and thus only neurons that 
have successfully established synaptic contacts with their target cells are able to survive 
(figure 3). Neurons lacking this trophic support are presumed to die by apoptosis. NTFs 
also regulate migration, differentiation, and maturation of post mitotic neuronal 
precursors and promote the regeneration of neurons from injury. (Airaksinen & Saarma, 
2002; Huang & Reichardt, 2001).  
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Figure 3. Neurotrophic factor hypotheses for peripheral nervous system development. Top: peripheral 
neurons that are initially produced in excess grow their axons toward their target regions of innervation. 
Middle: target cells produce and release limited quantities of neurotrophic factor, which is necessary to 
support survival of the developing neurons bearing the receptor for this factor. Growing axons compete for 
the factor. Bottom: those neurons that have established a proper contact with the target cell receive enough 
trophic factors to survive, whereas neurons that did not properly reach the target are eliminated by 
apoptosis. This way, the organism ensures a proper innervation of the target tissues while at the same time 
eliminating the neurons that fail to innervate any target cells. Reprinted from (Castrén, 2013). 
 
Although NTFs are also expressed in the developing and adult brain, there seems 
to be at least three general differences in the actions of neurotrophic factors in the Central 
Nervous System (CNS) when compared to the PNS. First, in the CNS, neurons project 
their axons to other neurons, and therefore the origin of NTFs is typically neuronal 
(although some factors are also expressed by glial cells), while in the PNS, NTFs are 
secreted by non-neuronal cells. Second, in the CNS, NTFs also support the extension and 
stabilization of dendritic arbors, axonal branches and synapses. Lastly, at least some 
NTFs are secreted in an activity-dependent way and not at a constant rate in small 
amounts as in the PNS. This action is particularly well characterized for BDNF, but may 
be shared by at least some other neurotrophic factors, such as NGF (Nerve growth factor) 
and GDNF (glial cell line-derived neurotrophic factor)  (Castrén, 2013).  
GDNF was discovered by its ability to promote the survival and morphological 
differentiation of DA neurons and to increase their high-affinity DA uptake (Lin, Doherty, 
Lile, Bektesh, & Collins, 1993). Together with neurturin (NRTN), artemin and persephin, 
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GDNF forms a distant group of neurotrophic factors in the transforming growth factor b 
(TGF-b) superfamily (Airaksinen & Saarma, 2002).  
Since GDNF and NRTN were shown to protect DA neurons in animal models of 
PD, hopes had been raised that these neurotrophic factors could be used as therapeutic 
agents for PD. Tested in clinical trials on PD patients, GDNF and NRTN revealed quite 
modest results so far. Direct infusion of GDNF protein into the putamen of 5 PD patients 
in an open-label study led to signiﬁcant clinical improvement within 3 months, but a 
subsequent double blinded phase II study showed no clinical efﬁcacy possibly because 
GDNF did not reach the target tissues. Technical differences between these two studies, 
especially in the delivery methods, could have contributed to the negative outcome (Gill 
et al., 2003) (Patel et al., 2005) (Slevin et al., 2005).  
NTRN was delivered to the brains of PD patients in two phase-2 trials using gene 
therapy. NRTN had statistically significant but modest clinical benefit only after a year 
of treatment (Bartus, Weinberg, & Samulski, 2014). Autopsy revealed that the poor 
diffusion of NRTN in brain tissue could be the main reason underlying the modest results. 
These clinical trials revealed that development of more efﬁcient NTF delivery 
systems is of utmost importance as well as to search for and study novel NTFs that could 
offer new therapeutic approaches for the treatment of neurodegenerative diseases. 
 
1.7 CDNF and MANF 
 
Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived 
neurotrophic factor (MANF) form a novel evolutionary conserved protein family that 
promotes the survival of DA neurons. CDNF and MANF differ from other neurotrophic 
factors due to their characteristic 3D structure, intracellular location and unparalleled dual 
mode of action. (Lindholm & Saarma, 2010; P. Lindholm et al., 2007; Petrova et al., 
2003). 
Although CDNF and MANF are mainly located in the ER, it has been shown that 
they can be secreted (P. Lindholm et al., 2007) (Apostolou, Shen, Liang, Luo, & Fang, 
2008; Palgi et al., 2009). 
The unique structure of CDNF and MANF consists of two domains, a saposin-
like N-terminal domain and a presumably unstructured carboxy (C)-terminal domain with 
an intradomain cysteine bridge in a CXXC motif. Knowing that saposin-like proteins 
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interact with lipids and/or membranes (Bruhn, 2005), it is suggested that the N-terminal 
domain of CDNF and MANF may also interact with lipids. Another possible attributed 
function for these NTFs comes from the C-terminal cysteine bridge which is similar to 
the active site motif of thiol/disulﬁde oxidoreductases that catalyze the formation of 
intramolecular disulphide bonds. These proteins include thioredoxins, like protein 
disulphide isomerases (PDIs), which function in the ER (Ellgaard & Ruddock, 2005). 
Interestingly, nitrosylated PDI is found in brain samples derived from PD patients, 
indicating a link between PDI dysfunction and protein misfolding in neurodegenerative 
disorders (Uehara et al., 2006). MANF and CDNF may facilitate the formation of cysteine 
bridges and protein folding in the ER, thus reducing the ER stress caused by unfolded or 
incorrectly folded proteins (figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Hypothetical modes of CDNF and MANF action. (A) Change in pH or lipid binding may 
induce dimerization of CDNF or MANF. (B) C-terminal domain of CDNF or MANF may facilitate the 
formation of disulﬁde bridges on secretory proteins in the ER. (C) CDNF or MANF may reduce disulﬁde 
bond on a transmembrane receptor protein on the cell surface. (D) CDNF or MANF may interact with the 
cell surface membrane and subsequently activate transmembrane receptor protein. Adapted from (Lindholm 
& Saarma, 2010). 
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1.8 Neuroprotective efficacy of CDNF and MANF 
 
CDNF seems to have no effect on cultured neurons dying due to deprivation of NTFs or 
treatment with genotoxic toxin etoposide, but efficiently protected and even repaired 
lesioned DA neurons in animal models of Parkinson’s disease, indicating a different mode 
of action when compared to classical neurotrophic factors (Airavaara et al., 2012; Paivi 
Lindholm et al., 2007).  
CDNF was tested in rat 6-OHDA model of PD showing efficient protection and 
even repair of SNpc DA neurons therefore improving the motor behaviour of lesioned 
animals (P. Lindholm et al., 2007).  CDNF also efficiently protects lesioned hippocampus 
in animal models of Alzheimer's disease (Kemppainen et al., 2015), but it has no influence 
on rat and mouse DA neurons in healthy rodents (Airavaara et al., 2012; Voutilainen et 
al., 2011).  
The mechanism of action of MANF may differ from CDNF. MANF expression 
induced by ER stress conditions has been shown by microarray analyses (Mizobuchi et 
al., 2007) (Tadimalla et al., 2008), suggesting that MANF has a role in the quality control 
of proteins during ER stress. Various studies in different cell lines and different conditions 
(hypoxia, myocardial infarction, tunicamycin-induced death, ischemia-induced death) 
which all induce ER stress, suggest that MANF has a protecting role against ER stress-
induced cell death (Apostolou et al., 2008; Glembotski et al., 2012; Tadimalla et al., 
2008). MANF selectively supports the survival of embryonic rat nigral DA neurons over 
that of GABAergic or serotonergic neurons in vitro (Petrova et al., 2003). 
Several studies show that MANF regulates the UPR and unresolved ER stress. 
MANF KO mice develop severe diabetes mellitus caused by increased β-cell apoptosis, 
where importantly, MANF-deficient mice show chronically activated UPR pathways 
(Lindahl et al., 2014). MANF interacts with GRP78 in the ER in a calcium-dependent 
manner suggesting that MANF and secretion is enhanced in pathological situations 
involving reduced ER calcium concentrations (Glembotski et al., 2012). Although there 
are still no studies showing CDNF’s role in regulating ER stress, its similar structure to 
MANF and ER location suggest that CDNF could have similar mode of action as MANF.  
CDNF has been shown to protect DA neurons in vitro from injury caused by α-synuclein 
oligomers (Latge et al., 2015). However, the exact mechanism of action of MANF and 
CDNF in the ER stress and UPR remains unclear. 
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1.9 GRP78 and neurodegeneration  
 
Evidence is accumulating that GRP78 plays important roles in cancer progression, 
malignancy, drug resistance, but interestingly also in neurodegenerative disorders. 
With aging, the balance between the protective and pro-apoptotic signalling in the 
UPR shifts, the pro-apoptotic signalling becoming more prominent with time (Hussain & 
Ramaiah, 2007; Naidoo et al., 2011; Paz Gavilan et al., 2006). ER structural alterations 
such as dispersed cisternae, (Hinds & McNelly, 1978), decline in GRP78 expression 
levels (Erickson, Dunning, & Holtzman, 2006) as well as activity (Nuss, Choksi, DeFord, 
& Papaconstantinou, 2008) propose that GRP78 could be a crucial factor for many age-
related neurodegenerative diseases such as PD and Alzheimer’s. 
Knowing that GRP78 expression and localization can change according to cell 
status, Bellani et al (2014) conducted a study where they suggest that accumulating 
extracellular α-synuclein induces an increase in surface-exposed GRP78, which becomes 
clustered in microdomains of the neuronal plasma membrane. α-synuclein interaction 
with cell surface GRP78 activates a signalling cascade leading to coﬁlin 1 protein 
inactivation and stabilization of microﬁlaments,  affecting morphology and dynamics of 
actin cytoskeleton in cultured neurons. Downregulation of GRP78 abolishes the activity 
of exogenous α-synuclein, suggesting it is α-synuclein’s primary target. The authors 
propose actin cytoskeleton modiﬁcation as the initial step in α-synuclein-induced 
neurodegeneration (Bellani et al., 2014). 
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2. Hypothesis  
 
As already mentioned, SNpc DA neurons are particularly vulnerable and are exposed to 
different stresses, especially ER stress. As age progresses, the balance between rescue 
mechanisms and apoptosis tends to become heavier on the apoptosis side, mainly due to 
the decline in expression and activity of chaperones and possibly to lack of trophic 
support.  
Due to CDNF and MANF’s ability to act on the ER (regulating ER stress and 
promoting survival) and to be secreted, there have to be specific receptors on the cell 
surface that mediate their actions. MANF and CDNF’s interaction with GRP78 shown in 
literature (Glembotski et al., 2012) and in Saarma’s group preliminary unpublished data 
reporting high affinity interaction between GRP78 with CDNF and MANF, together with 
GRP78’s ability to translocate to the cell surface and function as a receptor for different 
molecules. We tested the hypothesis that cell surface GRP78 could bind CDNF and 
MANF and serve as a receptor for extracellular CDNF and/or MANF mediating their 
survival promoting signalling. 
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3. Aims 
 
Aim 1 – Successfully build and clone the same vector as the one used by Burikhanov et 
al (2009): pDisplay™ Mammalian Expression Vector designed to target recombinant 
proteins to the surface of mammalian cells, to enable expression of membrane-targeted 
GRP78 (mGRP78). 
Aim 2 – Optimize transfection protocol for mGRP78 in different cell lines: HEK-293 and 
SH-SY5Y. 
Aim 3 – Monitor mGRP78 expression on the cell surface via Biotinylation and On-Cell 
Western. 
Aim 4 – Test whether extra-cellularly applied Par-4 induces apoptosis in cells transfected 
with mGRP78, as shown by Burikhanov et al (2009). 
Aim 5 – Study the binding between cell surface GRP78 and alkaline phosphatase linked 
CDNF or MANF. 
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4. Materials and Methods 
4.1 PCR & Cloning  
 
Building the plasmid for expressing GRP78 on the cell surface had a similar approach to 
the one described in Burikhanov et al (2009). The Human GRP78 cDNA sequence was 
amplified from a plasmid, generously given by Ave Eesmaa (Saarma Lab), by Polymerase 
Chain Reaction (PCR). pDisplay™, a mammalian expression vector designed to target 
recombinant proteins to the surface of mammalian cells, was purchased from Thermo 
Fisher Scientific Inc (MA, USA) (figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Map of pDisplayTM. 5.3 kb mammalian expression vector that allows display of proteins on the 
cell surface. Proteins expressed from pDisplay™ are fused at the N-terminus to the murine Ig κ-chain leader 
sequence, which directs the protein to the secretory pathway, and at the C-terminus to the platelet derived 
growth factor receptor (PDGFR) transmembrane domain, which anchors the protein to the plasma 
membrane, displaying it on the extracellular side. Recombinant proteins expressed from pDisplay™ contain 
the hemagglutinin A and myc epitopes for detection by western blot or immunofluorescence.  
28 
 
The whole procedure (PCR, restriction digestion and ligation) was performed first 
in silico using DNA sequence analysis software Serial Cloner to minimize the chances of 
cloning errors.  
To avoid the vector to ligate on itself and for the insert to be “automatically” in 
the correct orientation when the final construct is assembled, two different restriction 
enzymes giving non-compatible “sticky” ends that do not have restriction sites within the 
GRP78 insert were selected: SacII and SalI. 
SacII and SalI restriction sites, had to be added by PCR and so primers were 
designed to add SacII and SalI restriction sites to the GRP78 insert (table 2). 
 
SacII forward primer 5’-AAA TTT CCG C GG CAA GCT CTC CCT GGT GGC C-3’ 
SalI reverse primer 5’-ATA ATA G TC GAC CAA CTC ATC TTT TTC TGC TGT ATC CT-3’ 
 
Table 2. Primer sequences for amplifying GRP78 cDNA. The primers also introduce SacII and 
SalI restriction sites to the extremities of the GRP78 cDNA. Restriction sites are represented by the red 
arrows.  
 
PCR amplification was performed using Phusion® high fidelity DNA polymerase 
(New England Biolabs, New England, USA) to avoid the introduction of mutations. 
After the reaction, PCR products were purified using a PCR purification kit 
NucleoSpin® Gel and PCR Clean-Up, Macherey-Nagel (Düren, Germany). 
Restriction reaction to linearize pDisplay™ and digest GRP78 cDNA forming 
non-compatible “sticky” ends and in this way avoiding the vector to ligate on itself and 
enabling correct orientation of the cloning insert, was performed afterwards using Thermo 
Fisher Scientific FastDigest™ enzymes SacII and SalI with both vector and insert. This 
system allows for double and multiple digestions with any combination of enzymes. No 
sequential digestions or buffer changes are needed. 
A 0.8% agarose gel was run with the restriction reaction products and the correct 
bands, showing the predicted size obtained from Serial Cloner, were excised and purified 
by gel purification kit NucleoSpin® Gel and PCR Clean-Up (Macherey-Nagel). 
To assemble the vector and insert into the final construct, pDisplay-GRP78 
(named mGRP78), ligation reaction was made. Using T4 DNA ligase the two DNA 
components (pDisplay and GRP78) were attached together with phosphodiester bonds.  
To replicate mGRP78 exponentially, host E. coli able to take up foreign DNA 
from their environment (competent) must incorporate (transformation) and replicate our 
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construct. Only cells that have successfully incorporated the foreign DNA, which has an 
ampicillin resistance gene, should survive in an environment with selective pressure such 
as the presence of an antibiotic. Since mGRP78 has a ampicillin resistance gene, E. coli 
DH5α competent strain were transformed with both pDisplay empty vector and pDisplay-
GRP78, plated on Lysogeny broth (LB) agar plates with ampicillin antibiotic for selective 
growth and incubated at 37ºC overnight. The next day 6 colonies were picked from the 
pDisplay-GRP78 plates and 2 from pDisplay and were grown overnight in 2ml LB with 
ampicillin. 
Plasmid preparation, a technique to isolate plasmid DNA from bacteria, was 
performed using the commercial kit Plasmid DNA purification kit NucleoBond® Xtra 
Mini (Macherey-Nagel) with all 8 colonies. When bacteria are lysed 
under alkaline conditions both chromosomal DNA and proteins are denatured while the 
plasmid DNA remains stable. 
Using Serial Cloner uploaded with both sequences of pDisplay and pDisplay-
GRP78, a restriction digestion with EcoRI enzyme was performed in silico to predict the 
bands that would be originated after the restriction digestion, which would represent a 
correct cloning procedure. 
Diagnostic Restriction digestion was then performed with all 8 plasmids isolated from 
the corresponding 8 colonies and further analysed through gel electrophoresis.  
Two plasmids were then selected and sent to a sequencing service to assure the right 
assembly of vector with insert. All plasmids were stored at -20ºC waiting for sequencing 
results. 
Finally, 2 colonies (one mGRP78 and one pDisplay) were incubated separately in 
150ml medium with 100 ng/µl ampicillin and left to grow overnight at 37ºC with 222rpm. 
The next day midiprep following protocol from Plasmid DNA purification kit 
NucleoBond® Xtra Midi (Macherey-Nagel) was performed and 300µl of purified 
mGRP78 and pDisplay plasmid DNA were obtained (figure 6 for procedure overview).  
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Figure 6. Cloning procedure overview. 
 
4.2 Cell Culture, Transfection and Collection 
 
For this study two different cell lines were used: Human Embryonic Kidney 293 cells 
(HEK293) and SH-SY5Y human neuroblastoma cells. 
The two cell lines were cultured in DMEM medium supplemented with 10% Fetal 
Bovine Serum (FBS) and 0.2% normocin. 
All of the experiments were done in 96-well plates or 24-well plates 
(CELLSTAR® cell culture dishes, from Sigma-Aldrich, St. Louis, Missouri, EUA), with 
the plating and transfection procedures being optimised for each cell line and for each 
type of plate. 
Transfection of the plated cells with the construct mGRP78 was performed using 
Lipofectamine® 3000 Reagent (Thermo Fisher Scientific). Following the 
manufacturer’s protocol, two different concentrations of Lipofectamine 
reagent where tested in order to achieve maximum transfection efficiency.  
Transfection was done in both cell lines using 3 different plasmids: empty vector 
(pDisplay), construct (mGRP78) and green fluorescent protein (GFP). The latter was used 
as transfection efficacy control since it exhibits bright green fluorescence when exposed 
to light in the blue to ultraviolet range allowing visualization of transfected cells.  
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In each experiment, some of the cells were collected after transfection for 
expression control (western blot), using a modified RIPA (radio immunoprecipitation 
assay) Buffer (50mM Tris-HCl (pH 7.4), 0,25% sodium deoxycholate, 150mM NaCl, 
1mM EDTA, 1% IGEPAL, 1x protease/phosphatase inhibitor cocktail), which is a lysis 
buffer used to lyse cells and tissue. The components of this modified RIPA buffer are 
specially selected for better separation of the membrane proteins. After collection samples 
were homogenized using a 27G needle, centrifuged during 5 min at 10000rpm in a table-
top centrifuge and supernatant collected for further analyses. 
 
4.3 SDS-PAGE and Western blot 
 
Checking the expression of mGRP78 was accomplished by Sodium Dodecyl Sulfate-
Polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blot. Samples 
were mixed with loading buffer (62.5 mM Tris-HCl pH 6.8, 2.5 % SDS, 0.002 % 
Bromophenol Blue, 0.7135 M (5%) β-mercaptoethanol and 10 % glycerol), boiled at 95ºC 
for 5 min and then loaded on an 8% polyacrylamide gel where they were subjected to 
electrophoresis. After electrophoresis, the proteins present in the gel were transferred to 
a nitrocellulose membrane using Power Pac Basic device (Bio-Rad, Hercules, CA, USA) 
at constant 100 V for 75 min. During this step, the apparatus was placed on ice. After 
blotting the membrane was blocked with 3% milk in TBS (Tris-buffered saline) + 0.1% 
Tween (TBS-T) for 45 min before antibody incubations.   
 After finishing the blocking, the membrane was incubated with primary antibody, 
goat anti-GRP78 targeting c-20 region (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) (1:1000 dilution) in 3% milk TBS-T overnight at 4ºC. On the next day the 
membrane was washed with TBS-T 3x15 min, being afterwards incubated with the 
secondary antibody which targets the primary antibody. The secondary antibody used was 
IRDye® 680RD Donkey anti-goat from LI-COR (Lincoln, Nebraska, USA) (in 3% milk 
TBS-T, 1:10000), for 1h at room temperature and finally washed 3x15 min with TBS-T. 
This fluorescent antibody has absorption and emission wavelengths in the near-infrared 
spectrum. 
The membrane was revealed at Odyssey® CLx imaging system from LI-COR that 
measures infrared fluorescence signal which would be directly proportional to the amount 
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of target protein. The signal intensities of the revealed bands were quantified using the 
Odyssey® CLx software. 
One of the advantages of using near-infrared antibodies is the ability to label 
different proteins on the same membrane without having to strip it out of the 
previously used antibody due to the use of a secondary antibody with a 
different absorption and emission wavelength enabling two-color imaging. The 
same membrane was incubated directly with primary antibody mouse anti-actin (Sigma-
Aldrich) similarly as mentioned before for anti-GRP78 and latter incubated with IRDye® 
800CW Goat anti-mouse secondary antibody which has absorption and emission 
wavelengths in the near-infrared spectrum. Actin was used as a loading control.  
 
4.4 Immunostaining of cells plated on 96-well plates (On-cell 
Western) 
 
Once the HEK293 cells were transfected, in order to determine if the construct was 
expressed correctly on the cell surface, staining with antibodies against extracellular 
protein domains took place with unpermeabilized cells. 
Cells plated and transfected on a 96-well plate were fixed with 4% PFA 
(Paraformaldehyde), washed twice with PBS (Phosphate-buffered saline) and then 
incubated for 1 hour with blocking solution (5% horse serum in PBS) at room 
temperature. Next, cells were incubated overnight with primary antibody goat anti-
GRP78 c-20 (1:100 concentration in 5% horse serum, Santa Cruz Biotechnology) at 4ºC. 
On the next day, after washing the wells 3 times with PBS, cells were incubated 
for 1 hour at room temperature with IRDye® 680RD Donkey anti-goat secondary 
antibody (1:400 concentration in 5% horse serum), then after 3 more washes with PBS 
the plate was imaged using Odyssey® Clx from LI-COR.   
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4.5 Biotinylation 
 
Biotinylation is the process of covalently attaching biotin to a protein, and it can be used 
to enrich and purify proteins in different conditons due to biotin’s extremely high binding 
affinity to streptavidin, avidin or Neutravidin. The Pierce® Cell Surface Protein Isolation 
Kit (Thermo fisher Scientific) labels proteins that have accessible lysine residues and 
sufficient extracellular exposure. The isolation procedure uses a cell-impermeable, 
cleavable biotinylation reagent (Sulfo-NHS-SS-Biotin) to label exposed primary amines 
of proteins on the surface of intact adherent or suspension cells. Treated cells are then 
harvested, lysed and the labeled surface proteins are affinity-purified using Thermo Fisher 
Scientific NeutrAvidin Agarose Resin. Elution of the proteins bound to the resin is done 
using the kit’s elution buffer. The isolated cell surface proteins contain a small, 
nonreactive tag of the originally labeled primary amines but are no longer biotinylated 
(biotin remains bound to the resin). 
The procedure was carried out following the Kit’s protocol and adjusted for 24-
well plate. The resulting samples were further analysed by Western Blot, following the 
same methodology described previously. 
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4.6 Measuring Apoptosis through Caspase 3/7 assay  
 
As described by Burikhanov et al (2009), Par-4 binds to cell surface GRP78 and triggers 
apoptosis via activation of caspase-3. Programmed cell death (apoptosis) is achieved by 
inducing caspases which are proteases that degrade proteins indiscriminately and in this 
way killing the cell. Caspase-3 has a dominant role in the caspase cascade, which is a 
characteristic of the apoptotic pathway.  
Our aim was to check whether extracellular Par-4 would induce apoptosis on cell 
surface expressing GRP78 HEK293 cells and study the possible effects of CDNF and 
MANF on this apoptotis activation. To determine active caspase-3 and caspase-7 levels, 
Promega’s Caspase-Glo® 3/7 Assay (Promega Corporation, WI, USA) was used. The 
assay provides a proluminescent caspase-3/7 substrate, which contains the tetrapeptide 
sequence DEVD. This substrate is cleaved to release aminoluciferin, a substrate of 
luciferase. Cleavage of aminoluciferin by luciferase results in a chemoluminescent 
reaction. To test the assay we needed a positive control that would induce apoptosis on 
HEK293 cells via activation of caspase 3/7 and so cells were plated and treated on a 
white-walled 96-well plate (PerkinElmer, MA, USA) with 1 µM staurosporine (STS) for 
6h to determine best concentration that would give the highest signal. Staurosporine is a 
known apoptosis inducer by activation of caspase-3 (Kabir, Lobo, & Zachary, 2002). 
 After testing the kit, HEK293 cells were plated again on a white-walled 96-well 
plate, transfected with plasmids: GFP, pDisplay and mGRP78 and incubated with: 
vehicle, Par-4 100 nM and Par-4 500 nM for 24 hours. Afterwards caspase-3 activity was 
measured following Promega’s Caspase-Glo® 3/7 Assay Kit’s protocol. Luminescence 
values were determined using FLUOstar® OPTIMA from BMG LABTECH (Ortenberg, 
Germany). 
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4.7 Quantitative measurement of Alkaline Phosphatase 
activity on cell suspensions 
 
Testing the binding of MANF and CDNF to GRP78 on the cell surface was performed 
using Alkaline Phosphatase tagged MANF (AP-MANF) and Alkaline Phosphatase 
tagged CDNF (AP-CDNF) (Icosagen, Tartumaa, Estonia). Alkaline phosphatase is 
a hydrolase enzyme that removes phosphate groups from different molecules, 
including nucleotides, proteins, and alkaloids. For detecting AP activity, several 
substrates are available for AP that when catalysed produce a colorimetric or luminescent 
product that can be visualized and quantified. 
The protocol performed for accessing binding of MANF and CDNF to cell surface 
GRP78 used the AP substrate: para-Nitrophenylphosphate (pNPP) from Sigma-Aldrich. 
pNPP is a chromogenic used for spectrophotometric assays, where it is hydrolysed to the 
yellow product para-nitrophenol, which absorbs strongly at 405 nm wavelength and can 
be measured with visible light spectrophotometer. 
 For this protocol, HEK293 cells were used, since it was the cell line that we found 
having highest ectopic GRP78 expression levels. All of the steps of this protocol were 
performed at room temperature, and thus the cells would stay attached to the wells better. 
To rule out the hypothesis that AP was the binding partner of GRP78, some wells were 
incubated with alkaline phosphatase only. We also tested if the signal could be reduced 
by competition with a higher concentration of MANF or CDNF mixed with AP-MANF 
or AP-CDNF respectively. So HEK293 cells were again plated and transfected with GFP, 
pDisplay and mGRP78 on two 24-well plates. Two mGRP78 transfected wells were 
collected from each plate to check the expression of mGRP78 through Western blot. The 
remaining wells with pDisplay or mGRP78 transfected cells were washed with room 
temperature Dulbecco’s + 0.2% BSA (Bovine Serum Albumin) incubated with human 
placental AP or 10 nM AP-MANF or AP-CDNF or 100 nM MANF+AP-MANF or 100 
nM CDNF+AP-CDNF or Negative Control (Dulbecco’s + 0.2% BSA only) and incubated 
at room temperature for 1 hour (Figure 7).  
At the end of incubation AP-MANF and AP-CDNF solution was collected and 
stored for later to be used as positive control for the reaction with the substrate. Cells were 
washed 4x with room temperature Dulbecco’s + 0.2% BSA, lysed with Lysis Buffer (10 
mM Tris/HCl, 1% Triton X-100, pH 8), collected to Eppendorf tubes, vortexed for 30s, 
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allowed to sit at room temperature for 5 min, then vortexed again for 15s and centrifuged 
at 13000 rpm in a table-top centrifuge for 5 min. The supernatant was collected at the end 
of centrifugation. 
To inactivate endogenous AP, samples were heated at 65ºC for 10 min and then 
placed on ice to cool. Samples were pipetted in duplicate on a regular 96-well plate 
together with 2x pNPP substrate buffer (100 mg pNPP and 15 µl 1M MgCl2 into 15 ml 2 
M diethanolamine) in a 1:1 ratio. Positive control was made by mixing AP-MANF 
andAP-CDNF solution stored before with 2x pNPP substrate buffer. The 96-well plate 
was then incubated under aluminium foil until a visible colour was detected. The plate 
was then analysed for optic density at 405 nm using EnSpire® Multimode Plate Reader 
from PerkinElmer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Transfection and Incubation Map of the 24 well-plate. HEK293 cells were plated in every 
well and then transfected according to the color shown in the figure, being green wells transfected with 
pDisplay and red wells transfected with mGRP78. On the day of the experiment, cells from two wells were 
collected for Western blot control of mGRP78 expression (WB). As for incubations, wells A1-3 and D1-3 
were incubated with human placental Alkaline phosphatase, wells B1-3 and C1-3 were incubated with AP-
MANF or AP-CDNF and wells B4-6 and C4-6 were incubated with MANF + AP-MANF or CDNF + AP-
CDNF. Wells A4 and D4 were used as negative controls and well A6 as GFP transfection control.  
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4.8 Binding study between cell surface GRP78 and alkaline 
phosphatase tagged CDNF with different ligand 
concentrations. 
 
Using the same methodology as described in Quantitative measurement of Alkaline 
Phosphatase activity on cell suspensions, CDNF’s ability to bind in a concentration-
dependent manner to cell surface GRP78 was tested. HEK293 cells transfected with 
pDisplay and mGRP78 were incubated with different concentrations of AP-CDNF: 10 
nM, 5 nM, 1 nM and 0.1 nM. At the end of the protocol, samples were incubated with 
pNPP in a 96-well plate until a visible colour was detected and then analysed for optic 
density at 405 nm using EnSpire® Multimode Plate Reader from PerkinElmer. 
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4.9 Statistical analyses 
  
All graphics and their subsequent analyses were performed using software GraphPad 
Prism 7. Statistical analyses was done through one-way analysis of variance (one-way 
ANOVA) which is used to compare the means of three or more groups of samples. 
Tukey’s test for multiple comparisons between groups was used to determine statistical 
significance. 
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5. Results 
5.1 Quantification and Diagnostic restriction digestion of 
pDisplay and mGRP78 
 
Quantification using NanodropTM (Thermo Fisher Scientific) revealed the concentrations 
of both plasmids in the obtained 300 µl midiprep:  
- pDisplay: 1884 ng/µl 
- mGRP78: 1103 ng/µl  
Before being sent for sequencing, the final construct (mGRP78) was obtained by 
plasmid Miniprep of the 6 colonies and together with pDisplay (obtained also from 
Miniprep of the 2 other colonies) was subjected to restriction digestion with enzyme 
EcoRI (figure 8). The digestion revealed that the 3 bands obtained in mGRP78 correspond 
to the ones predicted in silico, therefore showing correct cloning procedure. The bands 
predicted in silico were:  
pDisplay: 
1. 5155 bp – Linearized by EcoRI[713] 
mGRP78: 
1. 5676 bp – from EcoRI[2316] to EcoRI[713] 
2. 1246 bp – from EcoRI[713] to EcoRI[1959] 
3. 357 bp – from EcoRI[1959] to EcoRI[2316]  
 
 
 
 
 
 
 
 
 
 
Figure 8. Diagnostic Restriction Digestion of 
pDisplay and mGRP78 with EcoRI. pDisplay and 
mGRP78 plasmids are shown in the image after 
restriction digestion with EcoRI.  
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5.2 mGRP78 sequence 
 
The sequence of the plasmids sent to sequencing was correct and it is the same as the one 
described in Burikhanov et al (2009). The GRP78 sequence was fused so that it would be 
in between an N-terminus with the murine Ig κ-chain leader sequence, which directs the 
protein to the secretory pathway, and a C-terminus with the platelet derived growth factor 
receptor (PDGFR) transmembrane domain, which anchors the protein to the plasma 
membrane, displaying it on the extracellular side (table 3). 
 
 
 
Ig κ-chain leader 
sequence 
Hemagglutinin A epitope   GRP78 cDNA c-Myc tag PDGFR transmembrane domain 
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACTATCCATA
TGATGTTCCAGATTATGCTGGGGCCCAGCCGGCCAGATCTCCCGGGATCCgcGGCAAGCTCTCCCTGGTGG
CCgcgatgctgctgctgctcagcgcggcgcgggccgaggaggaggacaagaaggaggacgtgggcacggtggtcggcatcgacctggggaccacctactcctgcgtcggc
gtgttcaagaacggccgcgtggagatcatcgccaacgatcagggcaaccgcatcacgccgtcctatgtcgccttcactcctgaaggggaacgtctgattggcgatgccgccaag
aaccagctcacctccaaccccgagaacacggtctttgacgccaagcggctcatcggccgcacgtggaatgacccgtctgtgcagcaggacatcaagttcttgccgttcaaggtg
gttgaaaagaaaactaaaccatacattcaagttgatattggaggtgggcaaacaaagacatttgctcctgaagaaatttctgccatggttctcactaaaatgaaagaaaccgctg
aggcttatttgggaaagaaggttacccatgcagttgttactgtaccagcctattttaatgatgcccaacgccaagcaaccaaagacgctggaactattgctggcctaaatgttatg
aggatcatcaacgagcctacggcagctgctattgcttatggcctggataagagggagggggagaagaacatcctggtgtttgacctgggtggcggaaccttcgatgtgtctcttc
tcaccattgacaatggtgtcttcgaagttgtggccactaatggagatactcatctgggtggagaagactttgaccagcgtgtcatggaacacttcatcaaactgtacaaaaagaa
gacgggcaaagatgtcaggaaagacaatagagctgtgcagaaactccggcgcgaggtagaaaaggccaaacgggccctgtcttctcagcatcaagcaagaattgaaattga
gtccttctatgaaggagaagacttttctgagaccctgactcgggccaaatttgaagagctcaacatggatctgttccggtctactatgaagcccgtccagaaagtgttggaagatt
ctgatttgaagaagtctgatattgatgaaattgttcttgttggtggctcgactcgaattccaaagattcagcaactggttaaagagttcttcaatggcaaggaaccatcccgtggca
taaacccagatgaagctgtagcgtatggtgctgctgtccaggctggtgtgctctctggtgatcaagatacaggtgacctggtactgcttgatgtatgtccccttacacttggtattga
aactgtgggaggtgtcatgaccaaactgattccaaggaacacagtggtgcctaccaagaagtctcagatcttttctacagcttctgataatcaaccaactgttacaatcaaggtct
atgaaggtgaaagacccctgacaaaagacaatcatcttctgggtacatttgatctgactggaattcctcctgctcctcgtggggtcccacagattgaagtcacctttgagatagat
gtgaatggtattcttcgagtgacagctgaagacaagggtacagggaacaaaaataagatcacaatcaccaatgaccagaatcgcctgacacctgaagaaatcgaaaggatgg
ttaatgatgctgagaagtttgctgaggaagacaaaaagctcaaggagcgcattgatactagaaatgagttggaaagctatgcctattctctaaagaatcagattggagataaag
aaaagctgggaggtaaactttcctctgaagataaggagaccatggaaaaagctgtagaagaaaagattgaatggctggaaagccaccaagatgctgacattgaagacttcaa
agctaagaagaaggaactggaagaaattgttcaaccaattatcagcaaactctatggaagtgcaggccctcccccaactggtgaagAGGATACAGCAGAAAAA
GATGAGTTGGtcgaCGAACAAAAACTCATCTCAGAAGAGGATCTGAATGCTGTGGGCCAGGACACGCAGGAG
GTCATCGTGGTGCCACACTCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCCCTGGTGGTGCT
CACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCACGTTAG 
 
 
Table 3. mGRP78 Open Reading Frame (ORF). Composed of Ig k-chain leader sequence, to target 
GRP78 to the secretory pathway, Hemagglutinin A epitope tag, human GRP78 cDNA, c-Myc tag and 
platelet derived growth factor receptor (PDGFR) transmembrane domain, to anchor the protein on the cell 
surface.  
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5.3 Transfection of HEK293 and SH-SY5Y cells 
 
Transfection with Lipofectamine® 3000 revealed that, HEK293 cells express the ectopic 
GRP78 in large amounts, and SH-SY5Y cells revealed to be more difficult to transfect  
with mGRP78 and show no sign of expression of ectopic GRP78 (figure 9), even though 
transfection clearly worked, as it was determined with GFP transfection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Transfection of HEK293 and SH-SY5Y cells with Lipofectamine® 3000. Control samples 
were not transfected, pDisplay and mGRP78 samples were transfected with the related plasmids. Primary 
antibody used (anti-GRP78 (c-20)) shows high specificity for detecting only GRP78 and ectopic GRP78. 
HEK293 cells express the ectopic GRP78, while SH-SY5Y seem to not express it at all.  
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5.4 Immunostaining of HEK293 cells reveals higher 
intensity in cells transfected with mGRP78 
 
To check if the ectopic GRP78 was on the cell surface, HEK293 cells were plated and 
transfected on a 96-well plate. To prevent the detection of the endogenous GRP78, the 
cells were not permeabilized. Clear difference is seen depending on which plasmid the 
cells were transfected with (figure 10). The main problem found executing this method 
was the great loss of cells from the wells due to extensive washing and incubations with 
cold solutions, which prevented us from quantifying these results. Nevertheless an 
increase in signal in the mGRP78 transfected wells is visible on the figure 10. 
 
 
 
 
 
 
 
 
 
Figure 10. Immunostaining of transfected and non-permeabilized HEK293 cells in 96-well plate with 
the antibody against GRP78. The dark signal arises from specific binding of the antibody to GRP78 on 
the cell surface. 
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5.5 Biotinylation of Cell Surface Proteins on Transfected 
HEK293   
 
Since the previous method for detecting GRP78 on the cell surface was not totally 
successful, Biotinylation using Pierce® Cell Surface Protein Isolation Kit (Thermo fisher 
Scientific) revealed successful transfection and expression of GRP78 on the cell surface 
of HEK293 cells. Actin, which is an intracellular protein was labeled afterwards as quality 
control for the Biotinylation (figure 11). The amount of actin biotinylated is almost 
inexistent compared to the actin detected in the other samples, suggesting a successful 
biotinylation of only the extracellular proteins.  The really weak signal detected in 
biotinylated protein fraction might be due to necrosis of some cells at the moment of 
biotinylation reaction (the membrane gets destroyed and therefore permeable) or due to 
breakdown of the membrane-impermeable sulfo-NHS-SS-biotin, allowing some isolated 
biotin to penetrate the cell and bind to actin. Quantification of  ectopic GRP78’s band’s 
intensities using Odyssey® software from LI-COR and comparing them to total protein 
sample mGRP78 band’s intensity reveals that 26% of the ectopic GRP78 gets 
biotinylated, suggesting that approximately 1/4 of the ectopic GRP78  gets located on the 
cell surface. It is known, as mentioned before in the review of literature, that endogenous 
GRP78 can in some situations be located on the cell surface, so it is not a surprise that its 
band is among the biotinylated ones.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Western blot of Cell surface proteins isolated with Pierce® Cell Surface Protein Isolation 
Kit and labeled with antibody against GRP78. 
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5.6 Apoptosis mediated by Par-4 in HEK293 cells with cell 
surface-targeted GRP78  
 
For testing the Promega’s Caspase-Glo® 3/7 Assay commercial kit to measure caspase-
3 dependent apoptosis activation, we treated cells with a known apoptotic drug, 
staurosporine. Figure 12 shows that staurosporine (STS) at the concentration of 1 µM 
induces apoptosis via activation of caspase-3 in HEK293 cells (6 hours incubation).  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 12. Measuring activation of caspase 3/7 using Promega’s Caspase-Glo® 3/7 Assay on HEK293 
cells. Vehicle – cells with normal medium, Dimethyl sulfoxide (DMSO) – cells incubated with medium 
containing DMSO, which was used to dissolve staurosporine, STS - cells incubated with 1 µM 
staurosporine in medium. Samples collected from 2 wells (n=2). 
 
Hoping to see an increased apoptosis in mGRP78 transfected HEK293 cells, we incubated 
cells transfected with pDisplay and mGRP78 for 24 hours with two different Par-4 
concentrations: 100 nM and 500 nM. When analysing figure 13 there seems to be 
increased caspase-3 activation signal when cells are incubated with par-4, but it looks 
independent of whether GRP78 is highly expressed on the cell surface or not. However, 
the fact that cells were in bad condition at the end of the experiment prevented from 
drawing any conclusion from it. The main problem found while executing this experiment 
was the time that it took for plating the cells on the 96-well plate, transfect and them 
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incubate for 24 hours with Par-4. This allowed the cells to grow over-confluent and 
therefore most of them were dying because of over-confluence rather than Par-4 
treatment.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Effects of Par-4 on caspase 3/7 activation on mGRP78 expressing HEK293 cells using 
Promega’s Caspase-Glo® 3/7 Assay. There seems to be an increase in caspase-3 activation when cells are 
incubated with Par-4, however there is no difference between the different transfections and the bad 
condition of the cells makes it impossible to draw any conclusions. Samples collected from 2 wells (n=2). 
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5.7 Quantitative binding study with AP-MANF 
 
Since the AP-MANF or AP-CDNF construct is composed of two proteins (alkaline 
phosphatase and MANF or CDNF) there was the possibility that alkaline phosphatase 
would be the binding partner of GRP78 and in this sense invalidating the interaction 
between MANF/CDNF and GRP78. Figure 14 shows that AP is not the binding partner 
of GRP78, suggested by the low signal of the AP sample in cells transfected with 
mGRP78 when compared to the AP-MANF incubation. Also, it seems we were able to 
compete the binding of AP-MANF with higher concentration of MANF as suggested by 
the difference between samples AP-MANF and AP-MANF+MANF on both transfection 
groups (pDisplay and mGRP78). However, there is no significant difference between 
pDisplay transfected cells and mGRP78 transfected cells, when comparing the 
incubations with AP-MANF or AP-MANF+MANF, stating that by using this method we 
were not able to convincingly show the binding between MANF and GRP78. 
 
Figure 14. Results of the quantitative binding study with MANF based on alkaline phosphatase 
reaction. A- AP-MANF binding experiment. Incubations: AP – Alkaline phosphatase, AP-MANF – 
Alkaline phosphatase tagged MANF, AP-MANF+MANF – Alkaline phosphatase tagged MANF + higher 
concentration of MANF. Cells transfected: pDisplay and mGRP78 plasmids. Intensities of the reaction 
were measured for Optic Density at 405 nm wavelength (O.D. 405 nm). Samples collected from 3 wells 
(n=3). Analyses through one-way ANOVA, Tukey’s test for multiple comparisons between groups 
(****=p-value<0.0001). B – Western blot of collected HEK293 cells transfected with mGRP78 at the 
beginning of the experiment for expression control (see figure 7). 
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5.8 Quantitative Binding study with AP-CDNF 
 
 
The binding study with AP-CDNF revealed that CDNF clearly binds with high affinity 
to cell surface GRP78 (figure 15). Adding a higher concentration of CDNF to the 
incubation with AP-CDNF would hopefully reduce the signal and suggest a real 
interaction between CDNF and GRP78, however, we were not able to reduce the signal. 
This was possibly due to over incubation time with pNPP substrate or due to the high 
amount of GRP78 on the cell surface, binding out a lot of the free CDNF, rendering our 
concentration of CDNF ineffective for competition with AP-CDNF.  
 
 
Figure 15.  Results of the quantitative binding study with CDNF based on Alkaline phosphatase 
reaction. A- AP-CDNF binding experiment. Incubations: AP – Alkaline phosphatase, AP-CDNF – 
Alkaline phosphatase tagged CDNF, AP-CDNF+CDNF – Alkaline phosphatase tagged CDNF + higher 
concentration of CDNF. Cells transfected: pDisplay and mGRP78 plasmids. Intensities of the reaction were 
measured for Optic Density at 405 nm wavelength (O.D. 405 nm). Samples collected from 3 wells (n=3). 
Analyses through one-way ANOVA, Tukey’s multiple comparisons test used to determine significant 
differences between groups (****=p-value<0.0001). B – Western blot of collected HEK293 cells 
transfected with mGRP78 at the beginning of the experiment for expression control (see figure 7).  
48 
 
5.9 Binding study between cell surface GRP78 and AP-
CDNF with different ligand concentrations. 
 
In this experiment by incubating pDisplay and mGRP78 transfected HEK293 cells with 
different concentrations of AP-CDNF, it was shown that the signal intensity increases as 
concentration of AP-CDNF increases in the cells transfected with mGRP78, while the 
cells transfected with pDisplay keep the signal constant regardless of the concentration 
of AP-CDNF. The concentration curve represented by figure 16, shows that the signal 
rises as the concentration rises in an almost linear way, therefore double the concentration, 
double the signal approximately, suggesting a real interaction/binding between CDNF 
and GRP78.       
 
 
Figure 16. Binding study between cell surface GRP78 and alkaline phosphatase tagged CDNF with 
different ligand concentrations. The blue line represents cells transfected with mGRP78, while the red 
line represents cells transfected with pDisplay. Samples collected from 4 wells (n=4) Analyses through 
one-way ANOVA, Tukey’s multiple comparisons test used to determine significant differences between 
groups. (****=p-value<0.0001). 
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6. Discussion 
 
In this work, we were able to show high interaction of the neurotrophic factor CDNF with 
GRP78. The competition experiment with incubation of AP-CDNF together with higher 
concentration of CDNF should be repeated by increasing the concentration of CDNF and 
shorter incubation time with the substrate. Next step in this interaction would be mutating 
the N-terminus or C-terminus of GRP78, rendering it non-functional at one of the 
terminals, and then incubate it with parts of CDNF (N- or C-terminus) tagged to alkaline 
phosphatase and check which  one gives the higher signal and therefore showing the 
actual interaction sites of the proteins. 
Unfortunately we failed to demonstrate the interaction between MANF and 
GRP78 with this method. This could happen mainly because of two reasons: first, the 
method used with alkaline phosphatase might not be sensitive enough to differentiate 
actual binding to unspecific binding when the interaction is not as strong as with CDNF 
for instance and second, the alkaline phosphatase might have interfered with the binding. 
Since alkaline phosphatase is much bigger molecule than MANF or CDNF, it could have 
gotten in the way of the interaction. This experiment should be repeated using a more 
sensitive method such as the use of a radioactive labeling which has almost no 
interference with the protein. 
One of the core objectives of this project was also to find a biological meaning for 
the interaction between cell surface GRP78 and the two neurotrophic factors. However, 
since we were not able to optimize the Par-4 experiment and due to the time window of 
the master thesis project, we could not test whether CDNF or MANF would compete with 
Par-4 for the binding to cell surface GRP78 and would for instance prevent apoptosis. 
This experiment should still be optimized and repeated in the future with Par-4 or other 
potential binding partners to GRP78 on the cell surface described in the literature. 
A particularly interesting issue is the fact that SH-SY5Y cells did not express the 
ectopic GRP78, especially when transfection is efficient with GFP. As shown by Bellani 
et al (2014), α-synuclein (which is produced in neurons) interaction with cell surface 
GRP78 can be noxious for the cells and in this way our transfected SH-SY5Y cells with 
mGRP78 might die, explaining why we don’t see the expression of the ectopic GRP78 
on SH-SY5Y cells. To study this, it would be interesting to knock-out α-synuclein 
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expression in this cell line, transfect with mGRP78 and then analyse the expression of the 
ectopic GRP78.  
 Eventually in the future, an experiment that I would like to do would be the 
transfection of primary DA neurons with mGRP78 and test the effects of CDNF or MANF 
together with α-synuclein preformed fibrils (PFF) for instance.  
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